Gryphon Bio

Executive Summary

Gryphon Bio is a clinical-stage diagnostics company developing novel blood tests for brain health, leveraging over two decades of -omic research to discover brain-specific molecular biomarkers. The company focuses on conditions such as traumatic brain injury (TBI) and Alzheimer's disease, aiming to provide non-invasive, accurate monitoring tools for patient journeys. By designing, validating, and manufacturing high-quality clinical blood tests, Gryphon Bio seeks to improve diagnostic accuracy and treatment outcomes in neurology. Founded in 2019 and headquartered in San Francisco, the company operates in the diagnostics space with a Phase 1 stage pipeline, reflecting its early but promising trajectory. Gryphon Bio addresses a significant unmet need in brain health diagnostics, where current methods are often invasive or lack sensitivity. The company's platform has the potential to transform patient management by enabling earlier detection and longitudinal monitoring. While still in early clinical stages, Gryphon Bio's approach is supported by robust biomarker discovery science. Key upcoming milestones include clinical data readouts and regulatory interactions that could validate its technology and attract strategic partnerships. The company's progress will depend on successful clinical validation and securing additional funding to advance its pipeline.

Upcoming Catalysts (preview)

• Q4 2026Top-line data from TBI biomarker clinical study70% success
• Q3 2026FDA breakthrough device designation for Alzheimer's blood test50% success
• Q2 2026Series B financing round60% success